A detailed history of Los Angeles Capital Management LLC transactions in Cerus Corp stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 195,224 shares of CERS stock, worth $349,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
195,224
Previous 76,944 153.72%
Holding current value
$349,450
Previous $135,000 151.11%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$1.7 - $2.39 $201,076 - $282,689
118,280 Added 153.72%
195,224 $339,000
Q4 2023

Feb 06, 2024

BUY
$1.25 - $2.35 $112 - $211
90 Added 0.12%
76,944 $166,000
Q3 2023

Nov 06, 2023

SELL
$1.5 - $3.07 $39,376 - $80,590
-26,251 Reduced 25.46%
76,854 $124,000
Q2 2023

Aug 03, 2023

BUY
$1.79 - $2.9 $33,800 - $54,760
18,883 Added 22.42%
103,105 $253,000
Q1 2023

May 04, 2023

SELL
$2.65 - $3.81 $21,226 - $30,518
-8,010 Reduced 8.68%
84,222 $250,000
Q4 2022

Feb 06, 2023

SELL
$3.38 - $4.22 $37,180 - $46,420
-11,000 Reduced 10.66%
92,232 $336,000
Q3 2022

Nov 02, 2022

BUY
$3.43 - $5.83 $75,525 - $128,370
22,019 Added 27.11%
103,232 $372,000
Q2 2022

Aug 05, 2022

BUY
$4.41 - $5.69 $11,466 - $14,794
2,600 Added 3.31%
81,213 $430,000
Q4 2021

Feb 03, 2022

SELL
$5.97 - $7.93 $4,143 - $5,503
-694 Reduced 0.88%
78,613 $535,000
Q3 2021

Nov 08, 2021

BUY
$4.79 - $6.68 $379,880 - $529,770
79,307 New
79,307 $483,000
Q2 2019

Jul 29, 2019

SELL
$4.51 - $6.6 $215,014 - $314,655
-47,675 Closed
0 $0
Q1 2019

Apr 25, 2019

SELL
$5.16 - $6.85 $48,751 - $64,718
-9,448 Reduced 16.54%
47,675 $297,000
Q4 2018

Feb 11, 2019

BUY
$4.89 - $7.16 $17,677 - $25,883
3,615 Added 6.76%
57,123 $290,000
Q2 2018

Jul 31, 2018

BUY
$5.19 - $7.25 $277,706 - $387,933
53,508 New
53,508 $357,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $317M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.